TRIFERIC® (ferric pyrophosphate citrate) solution
This slideshow reviews drug information for TRIFERIC, indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease.
Patients also experienced a reduction in left ventricular mass index.
Levocarnitine therapy may improve cardiac function and reduce left ventricular mass index in hemodialysis (HD) patients with carnitine deficiency and left ventricular hypertrophy (LVH), according to a recently published study.
In a prospective, open-label study, Terumi Higuchi, MD, PhD, of Keiai Hospital in Tokyo, and colleagues analyzed 148 HD patients randomly assigned to receive oral levocarnitine at a dose of 20 mg/kg/day for 12 months (75 patients) or to a control group (73 patients). The levocarnitine group experienced a 5.43% increase in ejection fraction from baseline to the end of the study, whereas the control group had a 0.14% decrease, a between-group difference of 5.57%, the researchers reported online ahead of print in the American Journal of Kidney Diseases. Left ventricular mass index decreased by 8.89 g/m2 from baseline to the end of the study in the levocarnitine group, but increased by 1.62 g/m2 in the control group, a between-group difference of 10.50 g/m2.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.